PASG News and Press, Passage Bio Inc. From 03/04/24

Continued momentum in upliFT-D trial of PBFT02 for the treatment of patients with frontotemporal dementia (FTD) with granulin mutations (GRN) with clinical trial site expansion into Europe and seven global sites now activated Pursuing new indications for PBFT02, including adult neurod...

Crescent Energy Company Class A (CRGY) is expected to report $0.21 for Q4 2023 ThredUp Inc. (TDUP) is expected to report $-0.13 for Q4 2023 Wright Investors` Service Holdings Inc (IWSH) is expected to report for Q4 2023 Bridgford Foods Corporation (BRID) is expected to report for Q1 2...

PHILADELPHIA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that management will participate in the following upcoming investor conferen...

PHILADELPHIA, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that William Chou, M.D., president and chief executive officer, will partici...

2023-12-20 14:20:15 ET More on Passage Bio Seeking Alpha’s Quant Rating on Passage Bio Historical earnings data for Passage Bio Financial information for Passage Bio For further details see: Passage Bio stock climbs 9% on dementia study, program up...

Dose 1 of PBFT02 achieved supraphysiologic CSF progranulin levels in each of the first three treated patients at 30 days after treatment Elevated progranulin levels were sustained at up to six months post-treatment Dose 1 of PBFT02 was generally well-tolerated in patients who re...

PHILADELPHIA, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced it has granted an inducement award to a new employee. Passa...

2023-11-13 07:38:59 ET More on Passage Bio Seeking Alpha’s Quant Rating on Passage Bio Historical earnings data for Passage Bio Financial information for Passage Bio For further details see: Passage Bio GAAP EPS of -$0.49 misses by $0.03

On track to present initial safety and biomarker data from three Cohort 1 patients in global Phase 1/2 upliFT-D trial of PBFT02 for the treatment of patients with frontotemporal dementia (FTD) with granulin mutations (GRN) in Q4 2023 Expect to report initial safety and biomarker dat...

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...